699 related articles for article (PubMed ID: 33743883)
1. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
2. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP
J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826
[TBL] [Abstract][Full Text] [Related]
3. Nurse-led initiation of hepatitis C care in rural Cambodia.
O'Keefe D; Samley K; Bunreth V; Marquardt T; Bobi SE; Antharo K; San Kim C; Sothy H; Sokha T; Samnang C; Sokchea Y; Hossain F; Balkan S; Le Paih M; Dousset JP
Bull World Health Organ; 2023 Apr; 101(4):262-270. PubMed ID: 37008268
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.
Bhat MA; Mir AN; Parry MA; Parray IA
Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):570-575. PubMed ID: 38725207
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
[TBL] [Abstract][Full Text] [Related]
10. Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Schulz TR; Kanhutu K; Sasadeusz J; Watkinson S; Biggs BA
J Telemed Telecare; 2020 Apr; 26(3):180-185. PubMed ID: 30336724
[TBL] [Abstract][Full Text] [Related]
11. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
[TBL] [Abstract][Full Text] [Related]
12. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
[TBL] [Abstract][Full Text] [Related]
13. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
Oru E; Trickey A; Shirali R; Kanters S; Easterbrook P
Lancet Glob Health; 2021 Apr; 9(4):e431-e445. PubMed ID: 33639097
[TBL] [Abstract][Full Text] [Related]
14. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Alavi M; Poustchi H; Merat S; Kaveh-Ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R
Int J Drug Policy; 2019 Oct; 72():99-105. PubMed ID: 31303262
[TBL] [Abstract][Full Text] [Related]
15. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
18. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
Indolfi G; Easterbrook P; Giometto S; Malik F; Chou R; Lucenteforte E
Liver Int; 2024 Mar; 44(3):663-681. PubMed ID: 38293756
[TBL] [Abstract][Full Text] [Related]
20. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
